Rithim Biologics
Rithim Biologics® is a gene therapy company focused on developing treatments for tachyarrhythmias, particularly atrial fibrillation (AF) and post-operative AF (POAF). Founded in March 2016, it develops gene therapies, delivery instruments, and kits to prevent or reduce fast heart rhythms, aiming to provide innovative solutions for cardiac rhythm management.
Industries
Nr. of Employees
small (1-50)
Rithim Biologics
P.O. Box 21 Woodbine, MD 21797
Patents
Products
Perioperative gene therapy delivery kit for prevention of postoperative atrial fibrillation
A combination product intended to deliver a therapeutic gene construct targeting cardiac ion-channel function during cardiac surgery or via less-invasive catheter approaches; kit components include a gene therapy vector and specialized delivery instrumentation for open-chest or minimally invasive procedures.
Perioperative gene therapy delivery kit for prevention of postoperative atrial fibrillation
A combination product intended to deliver a therapeutic gene construct targeting cardiac ion-channel function during cardiac surgery or via less-invasive catheter approaches; kit components include a gene therapy vector and specialized delivery instrumentation for open-chest or minimally invasive procedures.
Services
Research and development collaborations to advance gene therapies and delivery instrumentation for prevention or treatment of cardiac tachyarrhythmias, including perioperative applications.
Research and development collaborations to advance gene therapies and delivery instrumentation for prevention or treatment of cardiac tachyarrhythmias, including perioperative applications.
Expertise Areas
- Cardiac gene therapy
- Targeted cardiac delivery devices
- Preclinical cardiac electrophysiology
- Combination biologic/device product development
Key Technologies
- Viral vector gene delivery (adenoviral-type vectors)
- Catheter-based targeted cardiac delivery
- Epicardial/topical myocardial application techniques
- Combination product kit assembly (device + biologic)
News & Updates
Rithim Biologics® Inc. announced the issuance of its first patent, US 11,369,773 B2, covering targeted cardiac therapy using the DAAViS™ Catheter for delivering therapeutic compounds to the heart to treat conduction system disease, atrial fibrillation, myocardial infarction, and heart failure.
Issuance of US patent 11,369,773 B2 covering targeted cardiac therapy device and methods for delivering genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals, and biologics.
Rithim Biologics® Inc. announced the issuance of its first patent, US 11,369,773 B2, covering targeted cardiac therapy using the DAAViS™ Catheter for delivering therapeutic compounds to the heart to treat conduction system disease, atrial fibrillation, myocardial infarction, and heart failure.
Issuance of US patent 11,369,773 B2 covering targeted cardiac therapy device and methods for delivering genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals, and biologics.